The present invention relates to a pharmaceutical composition containing orlistat and a pharmaceutically acceptable bile acid sequestrant selected from a group comprising cholestyramine colestipol colesevelam colestimide sevelamer cellulose and dextran derivatives starch and starch derivatives and pharmaceutically acceptable salts thereof. The invention also relates to orlistat together with the bile acid sequestrant as a combined composition for simultaneous separate or sequential administratio...

The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid therapy to reduc e the capacity of nicotinic acid to induce flushing reactions in such individuals during nicotinic acid therapy. In accordance with the present invention the flush inhibiting agents are administered orally one to four times a day and preferably one to two times per day for between abou...

An oral administration form with a carrier for acid active sub-stances wherein the active substance has at least one free car-boxyl group ionically bound to a polymer having tertiary amino groups is characterized by the fact that the polymer is colestipol or colestipol hydrochloride.

Empleo de orlistat y un secuestrante de ácido biliar farmacéuticamente aceptable elegido del grupo constituido por colestiramina colestipol colesevelam colestimida sevelamer celulosa y derivados de dextrano almidón y derivados de almidón y sus sales farmacéuticamente aceptables para la preparación de un medicamento para la prevención y tratamiento de hipercolesterolemia.

Una composición farmacéutica que comprende orlistat y un secuestrante farmacéuticamente aceptable de ácidos biliares seleccionado de entre el grupo consistente en colestiramina colestipol colesevelam colestimida sevelamer derivados de la celulosa y del dextrano almidón y derivados del almidón y sales farmacéuticamente aceptables de éstos.

A pharmaceutical composition comprising orlistat and a bile acid sequestrant selected from cholestyramine, colestipol, coleselevam, colestimide, sevelamer, cellulose derivates, dextran derivatives, starch and starch derivatives is described. The composition is useful for the treatment or prevention of obesity. The bile acid sequestrant can be used in the manufacture of medicament for the treatment or prevention of gastrointestinal side effects selected from oily spotting, fatty/oily stools, feca...

1. A preparation comprising 1) at least one compound, from the group consisting of colestipol, colestyramine and active carbon which essentially prevents the enterohepatic circulation of the nucleotide synthesis inhibitors or a compound from the group consisting of uridine, purine, purine nucleotides or pyrimidine nucleotides which antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time, and 2) at least one nucleotide synthesis inhibitor from the group consistin...

1. A therapeutic combination comprising an effective amounts of first an ileal bile acid transport inhibiting compound and a second bile acid sequestering compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount of the compounds and wherein said ileal bile acid transport inhibiting compound is represented by formula (B-5): or enantiomers, racemates or a pharmaceutically acceptable salt thereof. 2. The therapeutic combination of c...